Supernus Pharmaceuticals, Inc.
SUPN Mid CapHealthcare · Drug Manufacturers - Specialty & Generic
Mis à jour: Jun 18, 2026, 22:21 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Supernus Pharmaceuticals, Inc. en bref
Supernus Pharmaceuticals, Inc. (SUPN) is currently trading at 38,73 € with a market capitalization of 2,2 Md €. The 52-week range spans from 26,90 € to 52,08 €; the current price is 25.6% below the yearly high. Year-over-year revenue growth stands at +38.6%.
💰 Dividende
Supernus Pharmaceuticals, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
6 analystes évaluent Supernus Pharmaceuticals, Inc. (SUPN) au consensus : Achat Fort. L'objectif de cours moyen est de 54,83 €, soit un potentiel de +41.58% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 48,00 € à 57,60 €.
Supernus Pharmaceuticals, Inc. : la thèse d'investissement en détail
Supernus Pharmaceuticals, Inc. (SUPN) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Top-line momentum is unusually strong with revenue expanding 38.6% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. With a gross margin near 74.13%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Strong Buy with an average price target implying roughly 41.58% upside from current levels — analyst sentiment is firmly constructive.
Le scénario baissier
Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. Short interest sits at 11.47% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.
À surveiller
- The analyst consensus price target implies 41.58% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.
Thèse d'investissement : forces et faiblesses
- Forte croissance du CA de 38.6% sur un an
- Marge brute élevée de 74.13% — signe d'un pouvoir de fixation des prix
- Consensus des analystes : Strong Buy
- Bilan solide avec faible endettement (D/E 3.8)
- Free cash flow positif
- –Actuellement non rentable
- –Positions vendeuses élevées (11.47%)
Aperçu technique
Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).
Profil de risque
The data points to relatively defensive market behavior, elevated short interest (11.47%).
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Supernus Pharmaceuticals, Inc.?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news